Cargando…

Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures

OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprost...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreas, Martin, Coti, Iuliana, Rosenhek, Raphael, Shabanian, Shiva, Mahr, Stephane, Uyanik-Uenal, Keziban, Wiedemann, Dominik, Binder, Thomas, Kocher, Alfred, Laufer, Guenther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381385/
https://www.ncbi.nlm.nih.gov/pubmed/30137264
http://dx.doi.org/10.1093/ejcts/ezy273
_version_ 1783396482362114048
author Andreas, Martin
Coti, Iuliana
Rosenhek, Raphael
Shabanian, Shiva
Mahr, Stephane
Uyanik-Uenal, Keziban
Wiedemann, Dominik
Binder, Thomas
Kocher, Alfred
Laufer, Guenther
author_facet Andreas, Martin
Coti, Iuliana
Rosenhek, Raphael
Shabanian, Shiva
Mahr, Stephane
Uyanik-Uenal, Keziban
Wiedemann, Dominik
Binder, Thomas
Kocher, Alfred
Laufer, Guenther
author_sort Andreas, Martin
collection PubMed
description OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprosthesis. METHODS: Five hundred consecutive patients, of whom 45.6% were female with a mean age of 73.5 [standard deviation (SD) 7.9 years], with severe aortic stenosis who received a rapid deployment aortic valve between May 2010 and July 2017 were included in a prospective and ongoing database. The median follow-up time was 12 months, and the total accumulated follow-up time was 818 patient years. Preoperative characteristics, operative parameters, survival, valve-related adverse events and valve haemodynamics were assessed. RESULTS: Thirty-day mortality was 0.8% (4/500), and overall survival at 1, 3 and 5 years was 94%, 89% and 81%, respectively. A minimally invasive surgical approach was chosen in 236 patients (47%), of which 122 (24%) were operated on through an anterior right thoracotomy. Cross-clamp and cardiopulmonary bypass times for isolated aortic valve replacement were 53 (SD 17) and 89 (SD 29) min for full sternotomy as well as 75 (SD 23) and 110 (SD 31) min for minimally invasive surgery approaches (P < 0.001). Mean gradients at discharge, 1, 3 and 5 years were 13 (SD 5), 11 (SD 4), 12 (SD 5) and 11 (SD 3) mmHg, respectively. New pacemaker implantation was necessary in 8.6% of patients. A single case (0.2%) of structural degeneration was registered after 6 years. Valve explantation for non-structural dysfunction or endocarditis occurred in 9 patients (1.8%). CONCLUSIONS: This rapid deployment aortic valve has shown excellent results concerning haemodynamic performance, durability and safety. Implantation requires specific training, and the rate of pacemaker implantation remains a matter of concern. This novel valve also facilitates minimally invasive approaches and may be beneficial in complex combined procedures.
format Online
Article
Text
id pubmed-6381385
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-63813852019-02-25 Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures Andreas, Martin Coti, Iuliana Rosenhek, Raphael Shabanian, Shiva Mahr, Stephane Uyanik-Uenal, Keziban Wiedemann, Dominik Binder, Thomas Kocher, Alfred Laufer, Guenther Eur J Cardiothorac Surg Conventional Valve Operations OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprosthesis. METHODS: Five hundred consecutive patients, of whom 45.6% were female with a mean age of 73.5 [standard deviation (SD) 7.9 years], with severe aortic stenosis who received a rapid deployment aortic valve between May 2010 and July 2017 were included in a prospective and ongoing database. The median follow-up time was 12 months, and the total accumulated follow-up time was 818 patient years. Preoperative characteristics, operative parameters, survival, valve-related adverse events and valve haemodynamics were assessed. RESULTS: Thirty-day mortality was 0.8% (4/500), and overall survival at 1, 3 and 5 years was 94%, 89% and 81%, respectively. A minimally invasive surgical approach was chosen in 236 patients (47%), of which 122 (24%) were operated on through an anterior right thoracotomy. Cross-clamp and cardiopulmonary bypass times for isolated aortic valve replacement were 53 (SD 17) and 89 (SD 29) min for full sternotomy as well as 75 (SD 23) and 110 (SD 31) min for minimally invasive surgery approaches (P < 0.001). Mean gradients at discharge, 1, 3 and 5 years were 13 (SD 5), 11 (SD 4), 12 (SD 5) and 11 (SD 3) mmHg, respectively. New pacemaker implantation was necessary in 8.6% of patients. A single case (0.2%) of structural degeneration was registered after 6 years. Valve explantation for non-structural dysfunction or endocarditis occurred in 9 patients (1.8%). CONCLUSIONS: This rapid deployment aortic valve has shown excellent results concerning haemodynamic performance, durability and safety. Implantation requires specific training, and the rate of pacemaker implantation remains a matter of concern. This novel valve also facilitates minimally invasive approaches and may be beneficial in complex combined procedures. Oxford University Press 2019-03 2018-08-20 /pmc/articles/PMC6381385/ /pubmed/30137264 http://dx.doi.org/10.1093/ejcts/ezy273 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Conventional Valve Operations
Andreas, Martin
Coti, Iuliana
Rosenhek, Raphael
Shabanian, Shiva
Mahr, Stephane
Uyanik-Uenal, Keziban
Wiedemann, Dominik
Binder, Thomas
Kocher, Alfred
Laufer, Guenther
Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
title Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
title_full Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
title_fullStr Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
title_full_unstemmed Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
title_short Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
title_sort intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
topic Conventional Valve Operations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381385/
https://www.ncbi.nlm.nih.gov/pubmed/30137264
http://dx.doi.org/10.1093/ejcts/ezy273
work_keys_str_mv AT andreasmartin intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT cotiiuliana intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT rosenhekraphael intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT shabanianshiva intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT mahrstephane intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT uyanikuenalkeziban intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT wiedemanndominik intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT binderthomas intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT kocheralfred intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures
AT lauferguenther intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures